88 related articles for article (PubMed ID: 34686073)
41. Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population.
Tkacz JP; Rance K; Waddell D; Aagren M; Hammerby E
Curr Med Res Opin; 2021 Jun; 37(6):957-965. PubMed ID: 33754932
[TBL] [Abstract][Full Text] [Related]
42. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
[TBL] [Abstract][Full Text] [Related]
43. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(27):1-118. PubMed ID: 23074405
[TBL] [Abstract][Full Text] [Related]
44. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment.
Kutikova L; Bowman L; Chang S; Long SR; Arning M; Crown WH
Leuk Lymphoma; 2006 Aug; 47(8):1535-44. PubMed ID: 16966264
[TBL] [Abstract][Full Text] [Related]
45. Herpes zoster-attributable resource utilization and cost burden in patients with solid organ transplant.
Palmer L; White RR; Johnson BH; Fowler R; Acosta CJ
Transplantation; 2014 Jun; 97(11):1178-84. PubMed ID: 24892964
[TBL] [Abstract][Full Text] [Related]
46. Informing health policy in Japan: A mixed-model estimation to compare the cost of illness of cervical cancer and endometrial cancer.
Hayata E; Seto K; Kitazawa T; Matsumoto K; Morita M; Hasegawa T
J Obstet Gynaecol Res; 2016 Apr; 42(4):446-56. PubMed ID: 26712320
[TBL] [Abstract][Full Text] [Related]
47. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
48. The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective.
Menzin J; White LA; Nichols C; Deniz B
BMC Health Serv Res; 2012 Dec; 12():459. PubMed ID: 23241078
[TBL] [Abstract][Full Text] [Related]
49. Increased healthcare costs by later stage cancer diagnosis.
McGarvey N; Gitlin M; Fadli E; Chung KC
BMC Health Serv Res; 2022 Sep; 22(1):1155. PubMed ID: 36096813
[TBL] [Abstract][Full Text] [Related]
50. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
51. Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.
Bhowmik D; Song X; Intorcia M; Kent ST; Shi N
J Oncol Pharm Pract; 2019 Jun; 25(4):855-864. PubMed ID: 29661050
[TBL] [Abstract][Full Text] [Related]
52. Disease and Economic Burden Associated with Recurrent Pericarditis in a Privately Insured United States Population.
Lin D; Laliberté F; Majeski C; Magestro M; Lejeune D; Duh MS; Lim-Watson M; Paolini JF
Adv Ther; 2021 Oct; 38(10):5127-5143. PubMed ID: 34417724
[TBL] [Abstract][Full Text] [Related]
53. The economic burden of brain metastasis among lung cancer patients in the United States.
Guérin A; Sasane M; Dea K; Zhang J; Culver K; Nitulescu R; Wu EQ; Macalalad AR
J Med Econ; 2016; 19(5):526-36. PubMed ID: 26735844
[TBL] [Abstract][Full Text] [Related]
54. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States.
Sieluk J; Slejko JF; Silverman H; Perfetto E; Mullins CD
Orphanet J Rare Dis; 2020 Sep; 15(1):260. PubMed ID: 32967697
[TBL] [Abstract][Full Text] [Related]
55. Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
J Med Econ; 2021; 24(1):469-478. PubMed ID: 33784916
[TBL] [Abstract][Full Text] [Related]
56. Overall care cost comparison between robotic and laparoscopic surgery for endometrial and cervical cancer.
Desille-Gbaguidi H; Hebert T; Paternotte-Villemagne J; Gaborit C; Rush E; Body G
Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):348-52. PubMed ID: 24135382
[TBL] [Abstract][Full Text] [Related]
57. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
58. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
[TBL] [Abstract][Full Text] [Related]
59. The cost to managed care of managing pulmonary hypertension.
Said Q; Martin BC; Joish VN; Kreilick C; Mathai SC
J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330
[TBL] [Abstract][Full Text] [Related]
60. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.
Pilon D; Teeple A; Zhdanava M; Ladouceur M; Ching Cheung H; Muser E; Lefebvre P
J Med Econ; 2019 Feb; 22(2):196-203. PubMed ID: 30523738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
